Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Aprea Therapeutics Inc (APRE)

Aprea Therapeutics Inc (APRE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 26,504
  • Shares Outstanding, K 52,998
  • Annual Sales, $ 0 K
  • Annual Income, $ -37,130 K
  • 60-Month Beta 0.87
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.97
Trade APRE with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.47
  • Most Recent Earnings -0.12 on 11/09/22
  • Next Earnings Date 03/21/23
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 237.29% ( -589.73%)
  • Historical Volatility 114.70%
  • IV Percentile 56%
  • IV Rank 10.30%
  • IV High 1,343.07% on 12/20/22
  • IV Low 110.30% on 08/12/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 0
  • Volume Avg (30-Day) 16
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 6,762
  • Open Int (30-Day) 9,744

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -0.13
  • Number of Estimates 2
  • High Estimate -0.12
  • Low Estimate -0.14
  • Prior Year -0.36
  • Growth Rate Est. (year over year) +63.89%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3361 +48.80%
on 01/03/23
0.6000 -16.65%
on 01/18/23
+0.1691 (+51.09%)
since 12/30/22
3-Month
0.3040 +64.51%
on 12/30/22
0.6980 -28.35%
on 11/04/22
-0.1688 (-25.24%)
since 11/01/22
52-Week
0.3040 +64.51%
on 12/30/22
2.2100 -77.37%
on 02/02/22
-1.6799 (-77.06%)
since 02/01/22

Most Recent Stories

More News
Aprea (APRE) Rises on Advancing Lead Drug to Clinical Studies

Aprea Therapeutics (APRE) advances its novel macrocyclic ATR inhibitor into early-stage clinical studies for treating advanced solid tumors.

SNY : 48.75 (-0.79%)
NVO : 139.08 (+0.22%)
ALLO : 7.97 (+3.24%)
APRE : 0.5001 (-0.28%)
Biotech Bid Up Following First Patient Dosage

A Boston-based %Biotech company is turning heads on Wednesday after the company announced that the first patient was dosed in its Phase 1/2a monotherapy clinical trial of ATRN-119, the Company’s lead...

APRE : 0.5001 (-0.28%)
4 Penny Stocks to Target Following the Latest Jobs Report

June inflation rose at the fastest pace since November 1981. However, the latest job report presented a healthy picture of the economy. Thus, we think penny stocks Annexon (ANNX), Aprea Therapeutics (APRE),...

ANNX : 7.20 (+0.84%)
APRE : 0.5001 (-0.28%)
ENDP : 0.2926 (-5.00%)
YSG : 1.6200 (unch)
Aprea Therapeutics Announces Acquisition of Atrin Pharmaceuticals Inc. and Reports First Quarter 2022 Financial Results

BOSTON, May 16, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing...

APRE : 0.5001 (-0.28%)
First Week of May 20th Options Trading For Aprea Therapeutics (APRE)

Investors in Aprea Therapeutics Inc saw new options begin trading this week, for the May 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the APRE options chain...

APRE : 0.5001 (-0.28%)
Aprea Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Update on Business Operations

BOSTON, March 15, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing...

APRE : 0.5001 (-0.28%)
Aprea Therapeutics, Inc. (APRE) Loses 21.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Aprea Therapeutics, Inc. (APRE) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts...

APRE : 0.5001 (-0.28%)
Biotech Stock Roundup: BMY Increases Dividend, MRNA's Study Results & More

Moderna's (MRNA) vaccine study results and other pipeline updates have been the biotech sector???s few key highlights during the past week.

BMY : 71.23 (-1.95%)
LLY : 342.57 (-0.46%)
MRNA : 174.30 (-1.00%)
APRE : 0.5001 (-0.28%)
FHTX : 8.90 (+3.49%)
Aprea Therapeutics Presents Primary Analysis from Phase 2 Trial of Eprenetapopt + Azacitidine for Post-Transplant Maintenance Therapy in TP53 Mutant MDS and AML at the 2021 American Society of Hematology (ASH) Annual Meeting

60% relapse free survival at 1 year post-transplant79% overall survival at 1 year post-transplantMedian overall survival of 20.6 months BOSTON, Dec. ...

APRE : 0.5001 (-0.28%)
Aprea (APRE) Reports FDA Removal of Clinical Hold on Study

The FDA removes its clinical hold on Aprea Therapeutics' (APRE) clinical study evaluating eprenetapopt combination study in lymphoid malignancies.

AZN : 63.56 (-2.77%)
RHHBY : 38.3200 (-2.12%)
ABBV : 146.60 (-0.78%)
APRE : 0.5001 (-0.28%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Aprea Therapeutics Inc. is a biopharmaceutical company. It is focused on developing and commercializing novel cancer therapeutics which reactivate the mutant tumor suppressor protein, p53. The Company's lead drug candidate, APR-246, a first-in-class small molecule p53 reactivator, is in clinical development...

See More

Key Turning Points

3rd Resistance Point 0.5454
2nd Resistance Point 0.5323
1st Resistance Point 0.5162
Last Price 0.5001
1st Support Level 0.4870
2nd Support Level 0.4739
3rd Support Level 0.4578

See More

52-Week High 2.2100
Fibonacci 61.8% 1.4819
Fibonacci 50% 1.2570
Fibonacci 38.2% 1.0321
Last Price 0.5001
52-Week Low 0.3040

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar